Thiazolidinediones and the risk of edema: A meta-analysis

This publication has 38 references indexed in Scilit:

• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  Published by Elsevier ,2005
• Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes
  Diabetic Medicine, 2005
• Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study
  Clinical Therapeutics, 2005
• Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes
  Diabetic Medicine, 2004
• Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea
  Acta Diabetologica, 2004
• Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone
  Diabetic Medicine, 2004
• Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
  Journal of Clinical Endocrinology & Metabolism, 2001
• Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
  Clinical Therapeutics, 2000
• Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
  Biochemical and Biophysical Research Communications, 2000
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
  Diabetes Care, 2000